Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048822 | 0.81 | CA12 (0.44) | P2RX7NOTUMMAOAL3MBTL1CA12 | |
| SCHEMBL29479281 | 0.81 | NOTUM (0.53) | P2RX7NOTUML3MBTL1CA12CA1 | |
| SCHEMBL3679115 | 0.81 | CA12 (0.48) | P2RX7NOTUMCA12CA1CA2 | |
| SCHEMBL31636683 | 0.79 | NOTUM (0.57) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL13727128 | 0.76 | RXRA (0.48) | CA12CA1CA2CA9ESRRA | |
| SCHEMBL2629357 | 0.75 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1CA12 | |
| SCHEMBL13119830 | 0.74 | P2RX7 (0.50) | P2RX7NOTUMMAOAL3MBTL1MIF | |
| SCHEMBL2885848 | 0.74 | NOTUM (0.55) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL3753209 | 0.74 | HTT (0.49) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL2829927 | 0.73 | KEAP1 (0.64) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-5739149-A | TREATING ASTHMA | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5635509-A | ASTHMA; BRONCHODILATOR AGENTS; VASODILATION MICROVASCULAR PERMEABILITY; MAST CELLS | ZENECA LIMITED (GB) | 1997-06-03 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | P2RX7 1337/4885NOTUM 3935/4885MAOA 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.